NDAORALTABLET
Approved
Apr 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine bromide) is an oral cholinesterase inhibitor approved in 1955 for myasthenia gravis and other neuromuscular conditions. It works by inhibiting acetylcholinesterase, thereby increasing acetylcholine concentration at the neuromuscular junction to improve muscle strength and function.
$7.0MPart D
LOE ApproachingDeclining brand with modest Part D footprint signals a mature, smaller commercial team focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Working on MESTINON offers stable, specialized expertise in a rare-disease neuromuscular niche with Bausch + Lomb's established infrastructure. However, LOE-approaching status and modest commercialization activity mean limited growth trajectory and smaller team size compared to growth-stage products.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.